Preclinical Evaluation of Postischemic Dehydroascorbic Acid Administration in a Large-Animal Stroke Model

Translational Stroke Research

Volumn 2, Issue 3, 2011, Pages 399-403

  Ducruet, Andrew F ^a   Mack, William J ^a   Mocco, J ^a   Hoh, Daniel J ^a   Coon, Alexander L ^a   D'Ambrosio, Anthony L ^a   Winfree, Christopher J ^a   Pinsky, David J ^a   Connolly, E Sander ^a,b  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NEUROLOGICAL INSTITUTE   (United States)

Author keywords

Acute stroke; Animal models; Antioxidants; Brain ischemia; Neuroprotection

Indexed keywords

DEHYDROASCORBIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BABOON; BRAIN INFARCTION SIZE; BRAIN PROTECTION; CONTROLLED STUDY; CRANIECTOMY; DRUG EFFECT; DRUG TREATMENT FAILURE; EXPERIMENTAL MODEL; MALE; NEUROLOGIC EXAMINATION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OCCLUSIVE CEREBROVASCULAR DISEASE; PRIORITY JOURNAL; STROKE; TREATMENT OUTCOME;

EID: 80052264760     PISSN: 18684483     EISSN: 1868601X     Source Type: Journal    
DOI: 10.1007/s12975-011-0084-2     Document Type: Article

References (25)

1. Brouns R, De Deyn PP. The complexity of neurobiological processes in acute ischemic stroke. Clin Neurol Neurosurg. 2009; 111(6): 483-95.
2. Doyle KP, Simon RP, Stenzel-Poore MP. Mechanisms of ischemic brain damage. Neuropharmacology. 2008; 55(3): 310-8.
3. Niizuma K, Endo H, Chan PH. Oxidative stress and mitochondrial dysfunction as determinants of ischemic neuronal death and survival. J Neurochem. 2009; 109 Suppl 1: 133-8.
4. Wolin MS, Davidson CA, Kaminski PM, Fayngersh RP, Mohazzab HK. Oxidant-nitric oxide signalling mechanisms in vascular tissue. Biochemistry (Mosc). 1998; 63(7): 810-6.
5. Gilgun-Sherki Y, Rosenbaum Z, Melamed E, Offen D. Antioxidant therapy in acute central nervous system injury: current state. Pharmacol Rev. 2002; 54(2): 271-84.
6. Chacon MR, Jensen MB, Sattin JA, Zivin JA. Neuroprotection in cerebral ischemia: emphasis on the SAINT trial. Curr Cardiol Rep. 2008; 10(1): 37-42.
7. Hall ED, Andrus PK, Smith SL, Oostveen JA, Scherch HM, Lutzke BS, et al. Neuroprotective efficacy of microvascularly-localized versus brain-penetrating antioxidants. Acta Neurochir Suppl. 1996; 66: 107-13.
8. Mack WJ, Mocco J, Ducruet AF, Laufer I, King RG, Zhang Y, et al. A cerebroprotective dose of intravenous citrate/sorbitol-stabilized dehydroascorbic acid is correlated with increased cerebral ascorbic acid and inhibited lipid peroxidation after murine reperfused stroke. Neurosurgery. 2006; 59(2): 383-8. Discussion 8.
9. Huang J, Agus DB, Winfree CJ, Kiss S, Mack WJ, McTaggart RA, et al. Dehydroascorbic acid, a blood-brain barrier transportable form of vitamin C, mediates potent cerebroprotection in experimental stroke. Proc Natl Acad Sci USA. 2001; 98(20): 11720-4.
10. Ducruet AF, Grobelny BT, Zacharia BE, Hickman ZL, Yeh ML, Connolly ES. Pharmacotherapy of cerebral ischemia. Expert Opin Pharmacother. 2009; 10(12): 1895-906.
11. Stroke Therapy Academic Industry Roundtable II (STAIR II). Recommendations for clinical trial evaluation of acute stroke therapies. Stroke. 2001; 32(7): 1598-606.
12. Fisher M, Feuerstein G, Howells DW, Hurn PD, Kent TA, Savitz SI, et al. Update of the stroke therapy academic industry roundtable preclinical recommendations. Stroke. 2009; 40(6): 2244-50.
13. Fisher M. Recommendations for advancing development of acute stroke therapies: Stroke Therapy Academic Industry Roundtable 3. Stroke. 2003; 34(6): 1539-46.
14. Huang J, Mocco J, Choudhri TF, Poisik A, Popilskis SJ, Emerson R, et al. A modified transorbital baboon model of reperfused stroke. Stroke. 2000; 31(12): 3054-63.
15. Mack WJ, Komotar RJ, Mocco J, Coon AL, Hoh DJ, King RG, et al. Serial magnetic resonance imaging in experimental primate stroke: validation of MRI for pre-clinical cerebroprotective trials. Neurol Res. 2003; 25(8): 846-52.
16. Mack WJ, King RG, Hoh DJ, Coon AL, Ducruet AF, Huang J, et al. An improved functional neurological examination for use in nonhuman primate studies of focal reperfused cerebral ischemia. Neurol Res. 2003; 25(3): 280-4.
17. Mocco J, Choudhri T, Huang J, Harfeldt E, Efros L, Klingbeil C, et al. HuEP5C7 as a humanized monoclonal anti-E/P-selectin neurovascular protective strategy in a blinded placebo-controlled trial of nonhuman primate stroke. Circ Res. 2002; 91(10): 907-14.
18. Mocco J, Mack WJ, Ducruet AF, King RG, Sughrue ME, Coon AL, et al. Preclinical evaluation of the neuroprotective effect of soluble complement receptor type 1 in a nonhuman primate model of reperfused stroke. J Neurosurg. 2006; 105(4): 595-601.
19. Ducruet AF, Mocco J, Mack WJ, Coon AL, Marsh HC, Pinsky DJ, et al. Pre-clinical evaluation of an sLe x-glycosylated complement inhibitory protein in a non-human primate model of reperfused stroke. J Med Primatol. 2007; 36(6): 375-80.
20. Sughrue ME, Mocco J, Mack WJ, Ducruet AF, Komotar RJ, Fischbach RL, et al. Bioethical considerations in translational research: primate stroke. Am J Bioeth. 2009; 9(5): 3-12.
21. Hoyte L, Kaur J, Buchan AM. Lost in translation: taking neuroprotection from animal models to clinical trials. Exp Neurol. 2004; 188(2): 200-4.
22. Quencer RM, Parker JC, Hinkle DK. Maturation of normal primate cerebral tissue: preliminary results of a computed tomographic-anatomic correlation. J Comput Assist Tomogr. 1980; 4(4): 464-5.
23. Johnson FC. The antioxidant vitamins. CRC Crit Rev Food Sci Nutr. 1979; 11(3): 217-309.
24. Bemeur C, Ste-Marie L, Desjardins P, Vachon L, Butterworth RF, Hazell AS, et al. Dehydroascorbic acid normalizes several markers of oxidative stress and inflammation in acute hyperglycemic focal cerebral ischemia in the rat. Neurochem Int. 2005; 46(5): 399-407.
25. Ekici F, Ozyurt B, Erdogan H. The combination of vitamin D3 and dehydroascorbic acid administration attenuates brain damage in focal ischemia. Neurol Sci. 2009; 30(3): 207-12.